Avingtrans Plc secure two national contracts to make safe nuclear waste

Avingtrans plc

Avingtrans plc (LON:AVG), which designs, manufactures and supplies critical components, modules, systems and associated services to the energy, medical and industrial sectors, has announced that Stainless Metalcraft (Metalcraft), part of the Group’s Energy and Medical division, has secured two national contracts that aim to make safe nuclear waste for long-term storage of the UK’s legacy of nuclear assets. Together, the contracts (one of which is a new contract and the other an extension to an existing contract) are valued at £14.5m and the additions boost Metalcraft’s forward order book to more than £75m over the next six years.

Metalcraft has been awarded the release of the next production phase of a contract to produce stainless steel waste containers that will be used to store intermediate level legacy waste. Additionally, Metalcraft has secured a contract from a new client to prepare concrete waste containers to support decommissioning of the now-retired fleet of UK nuclear power plants.

Nuclear decommissioning is a demanding but developing market that Metalcraft has specifically targeted in recent years. It has invested £7.5 million in new plant and equipment at its production facility to support the contracts, including modern CNC machine tools and robotic welding machines. Anticipating future demand, Metalcraft has also invested £3.4m in a new training facility to manage the supply of skilled personnel to meet anticipated demands of nuclear decommissioning. It is now ready to increase serial production of nuclear containers that meet rigorous specification criteria and proves the company’s ability to deliver highly specialised contracts.

Austen Adams, divisional managing director of Avingtrans PLC, commented:

“We are proud to be a part of this national mission of utmost importance. Winning these additional contracts is a testament to our production capability in Cambridgeshire and the incredible potential of our team members, who are highly skilled and ready to tackle these new challenges in the future decommissioning market.

“This challenge highlights the finest aspects of UK manufacturing while the benefit of a large forward order book enables us to invest in the people essential to the success of the challenge. We are looking forward to fulfilling these contracts and more to follow.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Avingtrans builds quantum supply chain opportunity

Avingtrans subsidiary Scientific Magnetics has shipped its 20th quantum computing magnet, with 18 more in production, strengthening its role in the quantum technology supply chain.

Avingtrans Secures Major Medical Milestone With Adaptix CE Certification, Singer Capital Markets

Avingtrans secures CE certification for Adaptix Ortho350, strengthening commercial opportunities in Europe and supporting long term medical growth ambitions.

Avingtrans’ Adaptix Ortho350 receives CE certification

Adaptix can now commercialise its compact 3D orthopaedic imaging system across UK and European healthcare markets.

Avingtrans highlights growing demand in nuclear and digital infrastructure markets

Avingtrans said its Advanced Engineering Systems division is seeing strong growth prospects, supported by renewed investment in nuclear energy, energy security and digital infrastructure, with over £10 million of recent nuclear orders and a broader pipeline in line with market expectations.

Avingtrans CEO Steve McQuillan highlights interim results and future growth areas

Steve McQuillan outlines Avingtrans’ stable first-half results, improved profitability, and expanding opportunities in nuclear energy, data centre cooling, and medical imaging.

Avingtrans Plc Building Momentum in Nuclear and Medical Imaging as Margins Surge (Video)

Avingtrans delivered improved margins and earnings in the first half, supported by stronger aftermarket activity and disciplined debt control. While revenue was flat year-on-year, management expects the usual second-half weighting to return, aided by nuclear contracts and rising data centre cooling demand. With Adaptix now FDA approved and US distributors appointed, medical imaging enters a critical commercial phase alongside growing exposure to AI-driven nuclear build-out.

Search